GAGuillermo Andrés

Guillermo Andrés

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Guillermo Andrés has a total of 105 co-authors. Here are the top co-authors by number of shared publications:

  • Javier C. Angulo

    Department of Urology Hospital Universitario de Getafe Getafe Spain

    24 shared publications
  • A. García-Tello

    10 shared publications
  • H. Gimbernat

    Servicio de Urología, Hospital Universitario de Getafe, Universidad Europea de Madrid, Madrid, España

    9 shared publications
  • Cristina Redondo

    Servicio de Urología, Hospital Universitario de Getafe, Departamento Clínico, Facultad de Ciencias Biomédicas, Universidad Europea de Madrid, Laureate International Universities, Madrid, España

    6 shared publications
  • F. Lista

    Servicio de Urología, Hospital Universitario de Getafe, Departamento Clínico, Facultad de Ciencias Biomédicas, Universidad Europea de Madrid, Madrid, España

    6 shared publications
  • I. Arance

    Servicio de Urología, Hospital Universitario de Getafe, Departamento Clínico, Facultad de Ciencias Biomédicas, Universidad Europea de Madrid, Laureate International Universities, Madrid, España

    6 shared publications

Latest Publications

  • The role of simulation in endourology training: development and validation of a 3D-printed model

    by S. Chiva, R. Polo Gay, C. Muñoz Bastidas, J. Colombas Vives, C. Gutierrez Castañé, P. Domenech, F.J. Diez-Caballero Alonso, M. Llorente Ortega, F.J. Ancizu Marckert, M. Torres Roca, et al.

  • What is the impact of post‐radical prostatectomy urinary incontinence on everyday quality of life? Linking Pad usage and International Consultation on Incontinence Questionnaire Short‐Form (ICIQ‐SF) for a COMBined definition (PICOMB definition)

    by Ángel García Cortés, Juan Colombás Vives, Cristina Gutiérrez Castañé, Santiago Chiva San Román, Pablo Doménech López, Francisco J. Ancizu Marckert, Mateo Hevia Suárez, Imanol Merino Narro, José M. Velis Campillo, Francisco Guillén Grima, et al.

    Aims: To identify the definition for urinary continence (UC) after radical prostatectomy (RP) which reflects best patients' perception of quality of life (QoL).Methods: Continence was prospectively assessed in 634 patients, 12 months after RP using the International Consultation on Incontinence Questionnaire Short‐Form (ICIQ‐SF) and the number of pads employed in a 24‐hour period (pad usage). We used the one‐way ANOVA technique with posthoc pairwise comparisons according to Scheffé's method (homogeneous subsets) for assessing the degree of QoL deficit related to urinary incontinence (UI).Results: The continence prevalence is 64.4%, 74.1%, 88.3%, and 35.8% using “0 pads,” “1 safety pad,” “1 pad,” and “ICIQ score 0” definitions, respectively. Pad usage is moderately strongly associated with ICIQ 1, 2, and 3 (ρ = 0.744, 0.677, and 0.711, respectively; p < 0.001). Concordance between classical UC definitions is acceptable between “0 pads—ICIQ score 0” (K = 0.466), but poor for “1 safety pad” and “1 pad” (K = 0.326 and 0.137, respectively). Patients with “0 pad usage” have better QoL related to urine leakage than patients with “1 safety pad” or “1 pad” (1.41 vs. 2.44 and 3.11, respectively; p < 0.05). There were no significant differences found regarding QoL between patients with ICIQ score 0 and ICIQ score 2 (1.01 vs. 1.63; p = 0.63).Conclusions: Pad usage and the ICIQ‐SF's answers provide useful information. We propose a combined definition (0 pads and ICIQ score ≤2) as it is the definition with the least impact on daily QoL.


  • La tromboprofilaxis quirúrgica en el día a día de la cirugía urológica: más allá de la terapia puente

    by P. Doménech López, J.E. Robles García, C. Gutiérrez Castañé, S. Chiva San Román, A. García Cortés, F.J. Ancizu Marckert, L.E. Tamariz Amador, G. Andrés Boville, F. Villacampa Aubá, F.R. de Fata Chillón, et al.


  • Is Robotic Partial Nephrectomy Safe for T3a Renal Cell Carcinoma? Experience of a High-Volume Center

    by Hiury S. Andrade, Homayoun Zargar, Oktay Akca, Onder Kara, Peter A. Caputo, Daniel Ramirez, Guillermo Andrés, Robert J. Stein, Shih-Chieh J. Chueh, Jihad H. Kaouk

    Purpose: To compare the oncological and functional outcomes of robotic partial nephrectomy (RPN) with radical nephrectomy (RN) in renal-cell carcinoma (RCC) cases with pT3a staging. Patients and Methods: A retrospective analysis of our IRB-approved nephrectomy database from 2005 to 2015 was performed. RPN and RN cases with confirmed RCC and pT3a staging were matched. Preoperative variables, functional, and oncological outcomes were compared between the groups, as well as Kaplan–Meier estimated overall survival (OS), cancer-specific survival (CSS), and recurrence-free survival (RFS). A multivariable Cox proportional hazards regression model for overall mortality rate was generated to evaluate hazard ratios (HRs) of potential risk factors. Results: Seventy patients with pT3a tumors composed each group. Preoperative variables were comparable between groups. The median follow-up time for the cohort was 20 (9–38) months and the renal function preservation was higher in the RPN group (86% vs 70%; p < 0.001). The estimated 3 years of OS (90% vs 84%; p = 0.42), CSS (94% vs 95%; p = 0.78), and RFS (95% vs. 100%; p = 0.06) were similar between RPN and RN groups, respectively. On multivariable Cox regression model, the presence of ≥2 aggressive tumor features was the only factor associated with increased risk of overall mortality rate (HR 4.01 95% confidence interval [1.13, 14.27)]; p = 0.03). Conclusion: Patients with localized pT3a RCC treated with RPN had similar short-term oncological and better renal functional outcomes compared with similar cases treated by RN. In the minimally invasive robotic surgery era, renal masses suspicious for pathological T3a disease should not be a deterring factor for performing nephron-sparing surgery when technically feasible by skilled surgeons.


  • Development of Castration Resistant Prostate Cancer can be Predicted by a DNA Hypermethylation Profile

    by Javier C. Angulo, Guillermo Andrés, Nadia Ashour, Manuel Sánchez-Chapado, Jose I. López, Santiago Ropero

    Detection of DNA hypermethylation has emerged as a novel molecular biomarker for prostate cancer diagnosis and evaluation of prognosis. We sought to define whether a hypermethylation profile of patients with prostate cancer on androgen deprivation would predict castrate resistant prostate cancer. Genome-wide methylation analysis was performed using a methylation cancer panel in 10 normal prostates and 45 tumor samples from patients placed on androgen deprivation who were followed until castrate resistant disease developed. Castrate resistant disease was defined according to EAU (European Association of Urology) guideline criteria. Two pathologists reviewed the Gleason score, Ki-67 index and neuroendocrine differentiation. Hierarchical clustering analysis was performed and relationships with outcome were investigated by Cox regression and log rank analysis. We found 61 genes that were significantly hypermethylated in greater than 20% of tumors analyzed. Three clusters of patients were characterized by a DNA methylation profile, including 1 at risk for earlier castrate resistant disease (log rank p = 0.019) and specific mortality (log rank p = 0.002). Hypermethylation of ETV1 (HR 3.75) and ZNF215 (HR 2.89) predicted disease progression despite androgen deprivation. Hypermethylation of IRAK3 (HR 13.72), ZNF215 (HR 4.81) and SEPT9 (HR 7.64) were independent markers of prognosis. Prostate specific antigen greater than 25 ng/ml, Gleason pattern 5, Ki-67 index greater than 12% and metastasis at diagnosis also predicted a negative response to androgen deprivation. Study limitations included the retrospective design and limited number of cases. Epigenetic silencing of the mentioned genes could be novel molecular markers for the prognosis of advanced prostate cancer. It might predict castrate resistance during hormone deprivation and, thus, disease specific mortality. Gene hypermethylation is associated with disease progression in patients who receive hormone therapy. It could serve as a marker of the treatment response.


  • Two-Port Approach Compared to Standard Laparoscopic Radical Cystectomy

    by Javier C. Angulo, Ana García-Tello, Erika Mateo, Helena Gimbernat, Cristina Redondo, Guillermo Andrés

    Background and Objectives: Two-port laparoscopic radical cystectomy (LRC) using a multichannel platform through the umbilicus and one additional 10-mm in the right iliac fossa has been recently described. We compare the perioperative and early results of this technique with a cohort of patients simultaneously treated in our institution with four-port LRC and a 7 to 10 cm midline incision. Materials and Methods: A matched-pair study comparing perioperative outcomes, postoperative visual analog pain scale (VAPS), and morbidity of two-port (n=30) and four-port (n=30) LRC. Preoperative and perioperative data analyzed and compared included demographics, type of urinary diversion, operative time, blood loss, transfusion requirements, decrease in serum hemoglobin, operative complications, analgesic needs, length of stay, number of nodes removed, and other pathologic information. Complications in the first 3 months were evaluated according to the Clavien–Dindo classification. Results: There was no significant difference between the two groups regarding patient age, gender, body–mass index, American Society of Anesthesiologists (ASA) score, Charlson comorbidity index, tumor stage, percent of positive nodes, positive margin rate, number of nodes retrieved, proportion of neobladders, secondary carcinoma in situ, incidental prostate cancer, or need of systemic chemotherapy. Median operative time was 20 minutes higher in the two-port procedure, but this difference was not statistically significant (p=0.2). Estimated blood loss and differential hemoglobin change were lower in the two-port technique (each p=0.03), but no difference was detected regarding the intraoperative or postoperative transfusion rate. Length of hospital stay was also equivalent. Differences were not observed either in the number or severity of complications. VAPS at days 2, 3, and 5 was significantly lower for two-port LRC (pConclusions: Two-port LRC performed through an umbilical platform and an accessory 10-mm port seems technically equivalent to standard four-port LRC. Perioperative outcomes regarding hospital stay and complications are tantamount. Diminished blood loss and, especially, less postoperative pain favor the reduced-port approach in this complex urologic minimally invasive procedure.


  • Actualización de los resultados de la rama española del Estudio aleatorizado europeo de screening del cáncer de próstata (ERSPC)

    by M. Luján, Á. Páez, J.C. Angulo, G. Andrés, H. Gimbernat, C. Redondo, G.M. Torres, A. Berenguer


  • Miniperc y Cirugía Retrógrada Intrarrenal: ¿cuándo y cómo?

    by F. Ramón de Fata, K. Hauner, G. Andrés, J.C. Angulo, M. Straub


  • V69 Percutaneous micronephrolithotomy: Surgical technique

    by F. Ramón De Fata, G. Andrés, H. Gimbernat, C. Redondo, E. Meilán, A. García-Tello, J.C. Angulo